Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The preDIlatation in tRanscathEter aortiC Valve implanTation Trial (DIRECT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02448927
Recruitment Status : Completed
First Posted : May 20, 2015
Last Update Posted : September 6, 2019
Sponsor:
Information provided by (Responsible Party):
Konstantinos Toutouzas, University of Athens

Brief Summary:
This is a randomized trial that will evaluate the role of balloon aortic valvuloplasty (BAV) on the outcome of patients undergoing transcatheter aortic valve implantation (TAVI) procedure. Patients will undergo a physical exam, coronary angiography and computed tomography angiography before TAVI. The randomization for direct or non-direct TAVI ( with BAV or without BAV) will take place 24 hours prior to the procedure by the core lab at Hippokration Hospital in Athens. The same lab will analyze in blind fashion the results of all the imaging modalities for each patient. The patients will be followed during the hospital stay and at 30 days and 1 year thereafter by echocardiography. The procedure of predilatation will be at the operator's discretion.

Condition or disease Intervention/treatment Phase
Aortic Valve Stenosis Device: balloon aortic valvuloplasty Device: Transcatheter Aortic Valve Implantation Phase 3

Detailed Description:

Background: Balloon aortic valvuloplasty (BAV) is a vital part of the transcatheter aortic valve implantation (TAVI) procedure. There is a lack of long-term evidence in patients undergoing direct TAVI without predilatation.

Trial: This is a prospective multi-center randomized trial.

Participating medical centers:

  1. 1st Department of Cardiology, Hippokration Hospital/Athens Medical School, Athens, Greece
  2. Heart Institute, Hadassah Hebrew University Medical Center, POB 12000, Jerusalem 91120, Israel.
  3. Department of Cardiology, Division of Internal Medicine, University Medical Centre Ljubljana, Zaloška 7, SI-1525 Ljubljana, Slovenia.
  4. Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece
  5. Second Department of Cardiology, University Hospital of Ioannina, Ioannina, Greece

Description: Patients will undergo a physical exam, coronary angiography and computed tomography angiography before TAVI. The randomization for direct or non-direct TAVI will take place 24 hours prior to the procedure by the core lab at Hippokration Hospital in Athens. The same lab will analyze in blind fashion the results of all the imaging modalities for each patient. The patients will be followed during the hospital stay and at 30 days and 1 year thereafter by echocardiography. The procedure of predilatation will be at the operator's discretion. Access sites for TAVI are: transfemoral, subclavian and transaortic.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 170 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The preDIlatation in tRanscathEter aortiC Valve implanTation Trial
Study Start Date : May 2015
Actual Primary Completion Date : May 2, 2018
Actual Study Completion Date : May 2, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
TAVI patients without balloon aortic valvuloplasty
Patients that will not undergo balloon aortic valvuloplasty (BAV) before transcatheter aortic valve intervention (TAVI) with the Medtronic Evolut R (or CoreValve).
Device: Transcatheter Aortic Valve Implantation
Other Name: TAVI

Active Comparator: TAVI patients with balloon aortic valvuloplasty
Patients that will undergo balloon aortic valvuloplasty (BAV) before transcatheter aortic valve intervention (TAVI) with the Medtronic Evolut R (or CoreValve).
Device: balloon aortic valvuloplasty
Other Name: BAV

Device: Transcatheter Aortic Valve Implantation
Other Name: TAVI




Primary Outcome Measures :
  1. Device success [ Time Frame: 30 days ]
    Device success, as designated by the VARC-2 criteria.


Secondary Outcome Measures :
  1. Death [ Time Frame: 30 days ]
    Death during the hospitalization of the patient, as designated by the VARC-2 criteria.

  2. Cerebrovascular accident [ Time Frame: 30 days and 1 year ]
    Cerebrovascular accident during and after the hospitalization of the patient, as designated by the VARC-2 criteria.

  3. New pacemaker implantation [ Time Frame: 30 days ]
    New pacemaker implantation during the hospitalization of the patient, as designated by the VARC-2 criteria.

  4. Vascular complications [ Time Frame: 30 days ]
    Vascular complications during the hospitalization of the patient, as designated by the VARC-2 criteria.

  5. Mortality [ Time Frame: after 30 days and at 1 year ]
    Death after discharge of the patient, as designated by the VARC-2 criteria.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diameter of >5mm for Evolut R and >6mm for CoreValve of the vessel.
  2. Aortic valve diameter of ≥20mm and ≤29mm as measured by echo.
  3. Ascending aorta diameter ≤ 43mm at the sinotubular junction.
  4. Severe aortic stenosis, defined as aortic valve area of < 1.0 cm2 (or aortic valve area index of < 0.6 cm2/m2) by the continuity equation, AND mean gradient > 40 mmHg or maximal aortic valve velocity > 4.0 m/sec by resting echocardiogram.
  5. STS score of ≥ 8 OR LogEuroSCORE> 20%, OR

    • 80 years old OR
    • 65 years old with 1 or 2 (but not more than two) from the following criteria:

      • Liver cirrhosis (Class A or B).
      • Pulmonary insufficiency: VMS<1 liter.
      • Previous heart surgery (CABG, vascular surgery).
      • Porcelain aorta.
      • Pulmonary artery systolic pressure >60 mmHg and high risk for heart surgery.
      • Relapsing pulmonary embolism.
      • Right ventricular insufficiency.
      • Thoracic wall injuries that contraindicate an open heart surgery.
      • History of radiation therapy of the mediastinum.
      • Connective tissue disease that contraindicates an open heart surgery.
      • Frailty/cachexia.
  6. Patients will be informed on the nature of the study and provide written consent.

Exclusion Criteria:

  1. A known hypersensitivity or contraindication to any of the following which cannot be adequately pre-medicated: aspirin or heparin and bivalirudin, ticlopidine and clopidogrel, nitinol (titanium or nickel), contrast media
  2. Ongoing sepsis, including active endocarditis.
  3. Any percutaneous coronary or peripheral interventional procedure with a bare metal or drug eluting stent performed within 30 days prior to Heart Team assessment.
  4. Echocardiographic evidence of LV or LA thrombus.
  5. Mitral or tricuspid valve insufficiency (> grade II).
  6. Previous aortic valve replacement (mechanical or bioprosthetic).
  7. Recent (within 6 months of Heart Team assessment) cerebrovascular accident (CVA) or transient ischemic attack (TIA).
  8. Patients with:

    Femoral, iliac or aortic vascular disease (stenosis etc) that precludes the insertion of a transcatheter sheath.

    OR Symptomatic carotid or vertebral artery disease (> 70% stenosis).

  9. The patient has a bleeding diathesis, coagulopathy or denies blood transfusion.
  10. Estimated life expectancy of less than 12 months due to associated non-cardiac co-morbid conditions.
  11. Creatinine clearance < 20 ml/min.
  12. Active gastritis or ulcer.
  13. Pregnancy.
  14. Severe left ventricular dysfunction with left ventricular ejection fraction (LVEF) < 20%.
  15. Unicuspid or bicuspid aortic valve.
  16. Mixed aortic valve disease (aortic stenosis and aortic regurgitation> 2+).
  17. Liver failure (Child-Pugh class C).
  18. Severe dementia (resulting in either inability to provide informed consent for the study/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits).
  19. Extreme aortic valve calcification and calcific asymmetry (if semiquantitively measured: grade 4, Agatston score: grade 4 AgS>5000 AU).
  20. Aortic valve area of < 0.4 cm2.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02448927


Locations
Layout table for location information
Greece
First Department of Cardiology, University of Athens
Athens, Attiki, Greece, 11527
Department of Cardiology, Onassis Cardiac Surgery Center
Athens, Greece
Second Department of Cardiology, University Hospital of Ioannina
Ioannina, Greece
Israel
Heart Institute Hadassah Hebrew University Medical Center
Jerusalem, Israel, 91120
Sponsors and Collaborators
National and Kapodistrian University of Athens
Investigators
Layout table for investigator information
Study Chair: Dimitrios Tousoulis, Professor University of Athens
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Konstantinos Toutouzas, Associate Professor of Cardiology, University of Athens
ClinicalTrials.gov Identifier: NCT02448927    
Other Study ID Numbers: DIRECT Trial
First Posted: May 20, 2015    Key Record Dates
Last Update Posted: September 6, 2019
Last Verified: September 2019
Keywords provided by Konstantinos Toutouzas, University of Athens:
transcatheter aortic valve implantation
Balloon aortic valvuloplasty
Aortic stenosis
TAVI
TAVR (transcatheter aortic valve replacement)
CoreValve
BAV
Evolut R
Additional relevant MeSH terms:
Layout table for MeSH terms
Aortic Valve Stenosis
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Ventricular Outflow Obstruction